Companies Abiomed
Abiomed (ABMD): executive pay, fiscal 2022
Free brief. Every figure links to the company’s own filing.
Abiomed no longer files a proxy statement; its last pay data is FY2022.
CEO vs. named peers78th pct.Of 19 peer CEOs
CEO pay, last three years
- $16,612,766FY2020
- $14,848,247FY2021
- $12,665,992FY2022
CEO total pay was $12,665,992 in fiscal 2022, down from $14,848,247 in fiscal 2021.
FY2022: salary $788,631 · bonus $0 · stock awards $6,557,724 · option awards $3,072,561
Frequently asked questions
Who was the highest-paid executive at Abiomed in fiscal 2022?
As disclosed, Michael Minogue (Chairman of the Board, President, Chief Executive Officer) was the highest-paid executive at Abiomed in fiscal 2022, with total compensation of $12,665,992.
How does Abiomed's chief executive pay compare to its disclosed peer group?
As disclosed, Michael Minogue's total compensation ranked at the 78th percentile of Abiomed's disclosed peer group.
What is Abiomed's CEO-to-median employee pay ratio?
As disclosed, Abiomed's CEO-to-median employee pay ratio was 96:1.
How did shareholders vote on Abiomed's executive compensation?
As disclosed, 36.09% of shareholders supported Abiomed's executive compensation in the latest say-on-pay vote.
How much does Abiomed spend in total on board compensation for fiscal 2022?
As disclosed, Abiomed reported total board compensation of $2,639,291 for fiscal 2022.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Minogue | $788,631 | $0 | $6,557,724 | $3,072,561 | $2,237,836 | $0 | $9,240 | $12,665,992 |
| Chairman of the Board, President, Chief Executive Officer | ||||||||
| Todd Trapp | 488,000 | 0 | 1,743,321 | 382,739 | 417,690 | 0 | 9,240 | 3,040,990 |
| Executive Vice President, Chief Financial Officer | ||||||||
| Andrew Greenfield | 345,340 | 0 | 1,737,360 | 293,737 | 450,366 | 0 | 9,240 | 2,836,043 |
| Executive Vice President and Chief Commercial Officer | ||||||||
| Marc Began | 395,887 | 0 | 1,444,960 | 303,262 | 413,513 | 0 | 9,240 | 2,566,862 |
| Executive Vice President, General Counsel | ||||||||
| David Weber | 450,307 | 0 | 762,786 | 508,919 | 555,986 | 0 | 9,240 | 2,287,238 |
| Former Senior Vice President and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Michael Minogue | $12,665,992 | $14,848,247 | $16,612,766 | ↓ −2,182,255 |
| Todd Trapp | 3,040,990 | 4,766,734 | 3,073,194 | ↓ −1,725,744 |
| Andrew Greenfield | 2,836,043 | 4,026,067 | 2,819,605 | ↓ −1,190,024 |
| Marc Began | 2,566,862 | 4,285,699 | — | ↓ −1,718,837 |
| David Weber | 2,287,238 | 4,204,804 | 2,662,043 | ↓ −1,917,566 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company maintains a strong pay-for-performance culture, aiming to tie executive compensation to performance objectives and long-term stockholder returns while attracting and retaining key executives with competitive compensation. The program heavily weights variable, incentive-based cash and stock compensation to align management's incentives with long-term business goals and stockholder interests.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Willis Towers Watson |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2022
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Marc Began | PSU | 2021-05-25 | — | 3,000 | — | 7,500 | $877,200 |
| Andrew Greenfield | PSU | 2021-05-25 | — | 4,000 | — | 10,000 | 1,169,600 |
| Michael Minogue | PSU | 2021-05-25 | — | 14,172 | — | 35,430 | 4,143,893 |
| Michael Minogue | OPTION | 2021-05-25 | — | — | 30,000 | — | 3,072,561 |
| Todd Trapp | OPTION | 2021-05-25 | — | — | 3,737 | — | 382,739 |
| Andrew Greenfield | OPTION | 2021-05-25 | — | — | 2,868 | — | 293,737 |
| Todd Trapp | PSU | 2021-05-25 | — | 4,000 | — | 10,000 | 1,169,600 |
| Andrew Greenfield | RSU | 2021-05-25 | — | — | 2,000 | — | 567,760 |
| Michael Minogue | RSU | 2021-05-25 | — | — | 8,503 | — | 2,413,832 |
| Marc Began | RSU | 2021-05-25 | — | — | 2,000 | — | 567,760 |
| David Weber | RSU | 2021-05-25 | — | — | 2,687 | — | 762,786 |
| Todd Trapp | RSU | 2021-05-25 | — | — | 2,021 | — | 573,721 |
| David Weber | OPTION | 2021-05-25 | — | — | 4,969 | — | 508,919 |
| Marc Began | OPTION | 2021-05-25 | — | — | 2,961 | — | 303,262 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Marc Began | $567,760 | $877,200 | $303,262 | 50.2% |
| Andrew Greenfield | 567,760 | 1,169,600 | 293,737 | 57.6% |
| Michael Minogue | 2,413,832 | 4,143,893 | 3,072,561 | 43.0% |
| Todd Trapp | 573,721 | 1,169,600 | 382,739 | 55.0% |
| David Weber | 762,786 | 0 | 508,919 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Weber | Option | 2,000 | 266.39 | — |
| Todd Trapp | Option | 2,334 | 266.39 | — |
| Andrew Greenfield | Option | 2,334 | 266.39 | — |
| David Weber | Option | 2,334 | 266.39 | — |
| Andrew Greenfield | Option | 2,868 | 283.88 | — |
| Marc Began | Option | 2,961 | 283.88 | — |
| Andrew Greenfield | Option | 3,264 | 223.9 | — |
| David Weber | Option | 3,334 | 223.9 | — |
| Marc Began | Option | 3,417 | 223.9 | — |
| Todd Trapp | Option | 3,737 | 283.88 | — |
| David Weber | PSU | 4,056 | — | 4,056 |
| Todd Trapp | Option | 4,354 | 223.9 | — |
| David Weber | Option | 4,969 | 283.88 | — |
| Andrew Greenfield | RSU | 7,139 | — | 7,139 |
| David Weber | RSU | 7,658 | — | 7,658 |
| Todd Trapp | RSU | 7,843 | — | 7,843 |
| David Weber | RSU | 8,197 | — | 8,197 |
| Andrew Greenfield | PSU | 8,300 | — | 8,300 |
| David Weber | PSU | 8,400 | — | 8,400 |
| Todd Trapp | PSU | 9,200 | — | 9,200 |
| Michael Minogue | Option | 13,392 | 223.9 | — |
| Michael Minogue | Option | 16,667 | 266.39 | — |
| Michael Minogue | RSU | 27,173 | — | 27,173 |
| Michael Minogue | Option | 30,000 | 283.88 | — |
| Michael Minogue | PSU | 31,784 | — | 31,784 |
| Michael Minogue | RSU | 34,978 | — | 34,978 |
| Todd Trapp | RSU | 49,970 | — | 49,970 |
| Andrew Greenfield | RSU | 49,970 | — | 49,970 |
| David Weber | RSU | 49,970 | — | 49,970 |
| Marc Began | RSU | 49,970 | — | 49,970 |
| Todd Trapp | PSU | 151,360 | — | 151,360 |
| Andrew Greenfield | PSU | 151,360 | — | 151,360 |
| David Weber | PSU | 151,360 | — | 151,360 |
| Marc Began | PSU | 151,360 | — | 151,360 |
| Todd Trapp | PSU | 979,200 | — | 795,702 |
| Michael Minogue | PSU | 1,080,855 | — | 1,080,855 |
| Andrew Greenfield | PSU | 1,213,108 | — | 637,546 |
| Marc Began | PSU | 1,233,180 | — | 658,374 |
| David Weber | PSU | 1,670,236 | — | 722,904 |
| Andrew Greenfield | RSU | 2,720,805 | — | 2,571,416 |
| Marc Began | RSU | 2,901,000 | — | 2,268,994 |
| Todd Trapp | RSU | 3,028,527 | — | 2,832,102 |
| David Weber | RSU | 3,051,051 | — | 3,051,051 |
| Michael Minogue | PSU | 3,997,116 | — | 3,997,116 |
| Michael Minogue | RSU | 10,459,235 | — | 9,799,073 |
| Michael Minogue | PSU | 152,655,185 | — | 152,655,185 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Paula A. JohnsonIndependent · Governance and Nominating | $50,932 | $448,959 | — | — | — | $499,891 |
| Dorothy E. PuhyIndependent · Lead Independent Director · Audit (Chair) · Risk and Compliance | 100,000 | 199,300 | — | — | — | 299,300 |
| Paul G. ThomasIndependent · Compensation (Chair) · Risk and Compliance | 70,000 | 199,300 | — | — | — | 269,300 |
| Martin P. SutterIndependent · Compensation · Governance and Nominating | 67,500 | 199,300 | — | — | — | 266,800 |
| Jeannine M. RivetIndependent · Audit · Compensation | 67,500 | 199,300 | — | — | — | 266,800 |
| Christopher D. Van GorderIndependent · Governance and Nominating · Risk and Compliance | 65,000 | 199,300 | — | — | — | 264,300 |
| Eric A. RoseIndependent · Audit | 60,000 | 199,300 | — | — | — | 259,300 |
| Myron L. RolleIndependent · Governance and Nominating · Risk and Compliance | 60,000 | 199,300 | — | — | — | 259,300 |
| W. Gerald AustenIndependent · Governance and Nominating | 55,000 | 199,300 | — | — | — | 254,300 |
| Michael R. MinogueEmployee director · Board Chair | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $200,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | $5 |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $595,932 |
| Equity awards (grant-date value) | $2,043,359 |
| All other compensation | $0 |
| Total cost of the board | $2,639,291 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Abiomed as a peer
Companies that benchmark against ABMD
No companies currently name ABMD as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2022
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
CNMD CONMED CorporationLIVN LivaNova PLCATRC Atricure, Inc.NVRO Nevro Corp.PEN Penumbra, Inc. Natus Medical IncorporatedTFX Teleflex IncorporatedAVNS Avanos Medical, Inc.MMSI Merit Medical Systems, Inc.DXCM DexCom, Inc.IART Integra LifeSciences Holdings CorporationINGN Inogen, Inc.RMD ResMed Inc.MASI Masimo CorporationNUVA NuVasive, Inc.ICUI ICU Medical, Inc.EW Edwards Lifesciences CorporationHAE Haemonetics CorporationGMED Globus Medical, Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Masimo Corporation | 2025 | Catherine Szyman | $850,048 | $16,388,693 | $1,399,998 | $1,130,000 | $19,797,140 |
| 2 | Edwards Lifesciences Corporation | 2025 | Bernard Zovighian | 1,192,500 | 7,167,024 | 6,499,109 | 2,406,537 | 17,454,255 |
| 3 | ResMed Inc. | 2026 | Michael Farrell | 1,272,895 | 9,749,468 | 3,249,907 | 1,738,857 | 16,201,649 |
| 4 | Merit Medical Systems, Inc. | 2025 | Fred Lampropoulos | 1,890,000 | 9,313,606 | 0 | 1,882,894 | 13,755,143 |
| 5 | Abiomed | 2022 | Michael Minogue | 788,631 | 6,557,724 | 3,072,561 | 2,237,836 | 12,665,992 |
| 6 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 7 | Nevro Corp. | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 8 | Avanos Medical, Inc. | 2025 | David Pacitti | 751,705 | 7,000,000 | 0 | 1,148,667 | 9,469,803 |
| 9 | Integra LifeSciences Holdings Corporation | 2025 | Mojdeh Poul | 1,009,616 | 5,219,868 | 2,250,011 | 174,563 | 9,375,551 |
| 10 | Atricure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 11 | NuVasive, Inc. | 2022 | J. Christopher Barry | 896,635 | 5,000,093 | 0 | 2,157,750 | 8,077,095 |
| 12 | LivaNova PLC | 2025 | Vladimir Makatsaria | 956,115 | 4,303,092 | 1,374,999 | 1,287,656 | 8,047,217 |
| 13 | DexCom, Inc. | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
| 14 | Conmed Corporation | 2025 | Patrick Beyer | 891,100 | 2,499,971 | 2,499,977 | 1,129,469 | 7,634,873 |
| 15 | Teleflex Incorporated | 2025 | Liam Kelly | 1,144,400 | 2,005,604 | 2,886,518 | 227,280 | 6,732,419 |
| 16 | ICU Medical, Inc. | 2025 | Vivek Jain | 775,000 | 4,500,023 | 0 | 1,162,500 | 6,452,042 |
| 17 | Globus Medical, Inc. | 2025 | Keith Pfeil | 479,467 | 0 | 2,982,347 | 783,000 | 4,400,159 |
| 18 | Inogen, Inc. | 2025 | Kevin R.M. Smith | 711,077 | 1,874,550 | 0 | 0 | 2,613,804 |
| 19 | Penumbra, Inc. | 2025 | Adam Elsesser | 850,000 | 0 | 0 | 0 | 851,621 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Abiomed | not disclosed | PSU 50 · RSU 30 · Option 20 | not disclosed | Willis Towers Watson |
| Atricure, Inc. | not disclosed | PSU 70 · RSU 30 | No | Korn Ferry |
| Avanos Medical, Inc. | 139% | PSU 50 · RSU 25 · Options 25 | No | Meridian Compensation Partners |
| Conmed Corporation | 126.8% | Options 50 · PSU 50 | Yes — rTSR | Compensia, Inc. |
| DexCom, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| Edwards Lifesciences Corporation | 127% | Options 50 · PSU 25 · RSU 25 | No | Semler Brossy Consulting Group |
| Globus Medical, Inc. | 102% | Options 100 | not disclosed | FW Cook |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| ICU Medical, Inc. | 150% | PSU 50 · RSU 50 | No | Compensia |
| Inogen, Inc. | 60% | RSU 50 · PRSU 50 | No | Aon |
| Integra LifeSciences Holdings Corporation | 40% | PSU 50 · Options 25 · RSU 25 | No | WTW |
| LivaNova PLC | 122.4% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Masimo Corporation | not disclosed | not disclosed | not disclosed | FW Cook |
| Merit Medical Systems, Inc. | 124.53% | PSU 60 · RSU 40 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Nevro Corp. | 53.7% | not disclosed | No | Aon |
| NuVasive, Inc. | 75% | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Penumbra, Inc. | not disclosed | not disclosed | No | Compensia |
| ResMed Inc. | not disclosed | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | FW Cook |
| Teleflex Incorporated | 25.9% | Options 55 · RSU 25 · PSU 20 | Yes — Absolute TSR | FW Cook |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2022 | 2022-08-10 | 14,295,971 | 25,312,782 | 27,070 | 36.09% | Failed |
| 2021 | 2021-08-11 | 18,897,024 | 17,843,575 | 1,366,980 | 51.43% | Passed |
| 2020 | 2020-08-12 | 34,620,618 | 2,249,262 | 83,636 | 93.9% | Passed |
| 2019 | 2019-08-07 | 18,333,903 | 15,575,542 | 1,215,571 | 54.07% | Passed |
| 2018 | 2018-08-08 | 30,013,981 | 1,560,457 | 924,127 | 95.06% | Passed |
| 2017 | 2017-08-09 | 31,813,975 | 1,319,441 | 57,139 | 96.02% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2022 | 2022-08-10 | 36.09%a |
| 2021 | 2021-08-11 | 51.43%b |
| 2020 | 2020-08-12 | 93.9%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 96 : 1 |
|---|---|
| CEO total compensation | $12,665,992 |
| Median employee compensation | $131,893 |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (55 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Michael Minogue. DEF 14A, filed 2022-06-28. Section “Summary Compensation Table”. As printed: 12,665,992. View filing ↗
- Section 01, Todd Trapp. DEF 14A, filed 2022-06-28. Section “Summary Compensation Table”. As printed: 3,040,990. View filing ↗
- Section 01, Andrew Greenfield. DEF 14A, filed 2022-06-28. Section “Summary Compensation Table”. As printed: 2,836,043. View filing ↗
- Section 01, Marc Began. DEF 14A, filed 2022-06-28. Section “Summary Compensation Table”. As printed: 2,566,862. View filing ↗
- Section 01, David Weber. DEF 14A, filed 2022-06-28. Section “Summary Compensation Table”. As printed: 2,287,238. View filing ↗
- Section 03, Marc Began PSU. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Greenfield PSU. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Minogue PSU. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Minogue OPTION. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Todd Trapp OPTION. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Greenfield OPTION. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Todd Trapp PSU. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Greenfield RSU. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Minogue RSU. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Marc Began RSU. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Weber RSU. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Todd Trapp RSU. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Weber OPTION. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Marc Began OPTION. DEF 14A, filed 2022-06-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2022-06-28. Section “CEO Pay Ratio”. As printed: 96 : 1. View filing ↗
- Section 08, Paula A. Johnson. DEF 14A, filed 2022-06-28. Section “Director Compensation”. As printed: 499,891. View filing ↗
- Section 08, Dorothy E. Puhy. DEF 14A, filed 2022-06-28. Section “Director Compensation”. As printed: 299,300. View filing ↗
- Section 08, Paul G. Thomas. DEF 14A, filed 2022-06-28. Section “Director Compensation”. As printed: 269,300. View filing ↗
- Section 08, Martin P. Sutter. DEF 14A, filed 2022-06-28. Section “Director Compensation”. As printed: 266,800. View filing ↗
- Section 08, Jeannine M. Rivet. DEF 14A, filed 2022-06-28. Section “Director Compensation”. As printed: 266,800. View filing ↗
- Section 08, Christopher D. Van Gorder. DEF 14A, filed 2022-06-28. Section “Director Compensation”. As printed: 264,300. View filing ↗
- Section 08, Eric A. Rose. DEF 14A, filed 2022-06-28. Section “Director Compensation”. As printed: 259,300. View filing ↗
- Section 08, Myron L. Rolle. DEF 14A, filed 2022-06-28. Section “Director Compensation”. As printed: 259,300. View filing ↗
- Section 08, W. Gerald Austen. DEF 14A, filed 2022-06-28. Section “Director Compensation”. As printed: 254,300. View filing ↗
- Section 08, Michael R. Minogue. DEF 14A, filed 2022-06-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-08-12. Item 5.07 · say-on-pay result. As reported: 36.09% (votes for as printed: 14,295,971). View filing ↗
- Section 06, 2021 vote. Form 8-K, filed 2021-08-13. Item 5.07 · say-on-pay result. As reported: 51.43% (votes for as printed: 18,897,024). View filing ↗
- Section 06, 2020 vote. Form 8-K, filed 2020-08-14. Item 5.07 · say-on-pay result. As reported: 93.9% (votes for as printed: 34,620,618). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 595,932 + equity 2,043,359 + all other 0 = 2,639,291, summed across the director compensation table rows.
- Masimo Corporation, Section 10b CEO total. 10-K/A, filed 2026-05-01. CEO total compensation as printed in Masimo Corporation's own proxy. As printed: 19,797,140. View filing ↗
- Edwards Lifesciences Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-26. CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. View filing ↗
- ResMed Inc., Section 10b CEO total. DEF 14A, filed 2026-10-01. CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 16,201,649. View filing ↗
- Merit Medical Systems, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in Merit Medical Systems, Inc.'s own proxy. As printed: 13,755,143. View filing ↗
- Abiomed (subject), Section 10b CEO total. DEF 14A, filed 2022-06-28. CEO total compensation as printed in Abiomed's own proxy. As printed: 12,665,992. View filing ↗
- Haemonetics Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. View filing ↗
- Nevro Corp., Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro Corp.'s own proxy. As printed: 11,453,548. View filing ↗
- Avanos Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-12. CEO total compensation as printed in Avanos Medical, Inc.'s own proxy. As printed: 9,469,803. View filing ↗
- Integra LifeSciences Holdings Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Integra LifeSciences Holdings Corporation's own proxy. As printed: 9,375,551. View filing ↗
- Atricure, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Atricure, Inc.'s own proxy. As printed: 9,217,620. View filing ↗
- NuVasive, Inc., Section 10b CEO total. DEF 14A, filed 2023-05-08. CEO total compensation as printed in NuVasive, Inc.'s own proxy. As printed: 8,077,095. View filing ↗
- LivaNova PLC, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in LivaNova PLC's own proxy. As printed: 8,047,217. View filing ↗
- DexCom, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. View filing ↗
- Conmed Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Conmed Corporation's own proxy. As printed: 7,634,873. View filing ↗
- Teleflex Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Teleflex Incorporated's own proxy. As printed: 6,732,419. View filing ↗
- ICU Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in ICU Medical, Inc.'s own proxy. As printed: 6,452,042. View filing ↗
- Globus Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Globus Medical, Inc.'s own proxy. As printed: 4,400,159. View filing ↗
- Inogen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Inogen, Inc.'s own proxy. As printed: 2,613,804. View filing ↗
- Penumbra, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Penumbra, Inc.'s own proxy. As printed: 851,621. View filing ↗